Litcius/Paper detail

Saroglitazar, a Dual PPAR α/γ Agonist, Improves Atherogenic Dyslipidemia in Patients With Non-Cirrhotic Nonalcoholic Fatty Liver Disease: A Pooled Analysis

Mohammad Shadab Siddiqui, Dhruvanshu Parmar, Farheen Sheikh, Shiv Kumar Sarin, Laura M. Cisneros, Samer Gawrieh, Taufik Momin, Ajay Duseja, Arun J. Sanyal

2023Clinical Gastroenterology and Hepatology40 citationsDOI

Topics & Concepts

MedicineInternal medicineEndocrinologyDiabetes mellitusPlaceboTriglycerideCholesterolNonalcoholic fatty liver diseaseLipoproteinGastroenterologyFatty liverDiseasePathologyAlternative medicineLiver Disease Diagnosis and TreatmentLiver Disease and TransplantationPeroxisome Proliferator-Activated Receptors
Saroglitazar, a Dual PPAR α/γ Agonist, Improves Atherogenic Dyslipidemia in Patients With Non-Cirrhotic Nonalcoholic Fatty Liver Disease: A Pooled Analysis | Litcius